CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

Abstract

CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.

• Authors: E Marangoni, N Lecomte, L Durand, G de Pinieux, D Decaudin, C Chomienne, F Smadja-Joffe, M-F Poupon
• Journal: British journal of cancer (Br J Cancer) Vol. 100 Issue 6 Pg. 918-22 (Mar 24 2009) ISSN: 1532-1827 [Electronic] England
• PMID: 19240712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Cd44 protein, mouse
• Hyaluronan Receptors

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Female
• Humans
• Hyaluronan Receptors (analysis, immunology, physiology)
• Mammary Neoplasms, Experimental (chemistry, drug therapy, pathology)
• Mice
• Neoplasm Recurrence, Local (prevention & control)
• Xenograft Model Antitumor Assays